

## **Remarks**

### **Amendments to the Specification**

The amendments to the specification, as detailed above, merely provides the necessary priority information for this application. Applicant respectfully submits that no new matter is presented with these amendments.

### **Claim Amendments**

The amendments to the claims, as detailed above, merely seek to place the application in a format that conforms to United States patent practice. Claims 1-53 were pending. Applicant has cancelled claims 17 and 50-53; amended claims 5-14, 16, 18-19, 21-23, 25, 27-28, 31, 36 and 41 to remove multiple dependencies; and corrected the Markush language in claims 15, 21-22 and 24. Applicant has also made other specific claim amendments that are described individually below.

**Claim 1:** An unnecessary use limitation has been canceled from composition claim 1.

**Claim 7 (and 54):** A “preferable” limitation has been canceled from claim 7. Applicant has added new claim 54 to cover the subject matter that was cancelled from original claim 7 by this amendment.

**Claim 16 (and 55):** Claim 16 has been amended such that it depends from claim 7 instead of claims 7 or 8. Applicant has added new claim 55 to cover the subject matter that was cancelled from original claim 16 by this amendment.

**Claim 19 (and 56):** A “for example” limitation has been canceled from claim 19. Applicant has added new claim 56 to cover the subject matter that was cancelled from original claim 19 by this amendment.

**Claim 20:** Several inadvertent and obvious errors in chemical nomenclature have been corrected in claim 20.

**Claim 21 (and 57-62):** Several “for example” limitations have been canceled from claim 21. Applicant has added new claims 57-62 to cover the subject matter that was cancelled from original claim 21 by these amendments.

**Claim 30:** A “pharmaceutically acceptable carrier” has been added as an element of claim 30 in order to differentiate it from claim 1. Support for this amendment can be found throughout the specification, e.g., see pp. 20-22.

**Claim 31 (and 66-71):** Claim 31 has been amended such that it depends from claim 2 or 3 instead of any one of claims 2-29. Applicant has added new claims 66-71 to cover certain subject matter that was cancelled from original claim 31 by this amendment (specifically the embodiments of claims 6, 7, 15, 16, 23 and 29).

**Claim 33 (and 63):** A “for example” limitation has been canceled from claim 33. Applicant has added new claim 63 to cover the subject matter that was cancelled from original claim 33 by this amendment.

**Claim 36 (and 72-77):** Claim 36 has been amended such that it depends from claim 2 or 3 instead of any one of claims 2-29. Applicant has added new claims 72-77 to cover certain subject matter that was cancelled from original claim 36 by this amendment (specifically the embodiments of claims 6, 7, 15, 16, 23 and 29).

**Claim 38 (and 64):** A “for example” limitation has been canceled from claim 38. Applicant has added new claim 64 to cover the subject matter that was cancelled from original claim 38 by this amendment.

**Claim 41:** An error in antecedent basis has been corrected in claim 41.

**Claim 44 (and 65):** A “for example” limitation has been canceled from claim 44. Applicant has added new claim 65 to cover the subject matter that was cancelled from original claim 44 by this amendment.

**Claim 49 (and 78-83):** Claim 49 has been amended such that it depends from claim 2 or 3 instead of any one of claims 2-10 or 12-27. Applicant has added new claims 78-83 to cover certain subject matter that was cancelled from original claim 49 by this amendment (specifically the embodiments of claims 6, 7, 15, 16, 23 and 29).


No new matter has been added by way of these claim amendments.

Conclusion

Applicant respectfully requests entrance of these amendments into the National Stage application that is filed herewith. Please charge any fees associated with this filing, or apply any credits, to our Deposit Account No. 03-1721.

Respectfully submitted,

Dated: June 28, 2004

  
\_\_\_\_\_  
Charles Lyon, Ph.D.  
Agent for Applicant  
Limited Recognition Under 37 C.F.R. § 10.9(b)

CHOATE, HALL & STEWART  
Exchange Place  
53 State Street  
Boston, MA 02109  
(617) 248-5000

3713764\_1.DOC